Patent SG-11201908598P-A (SG)
Title: Compounds useful in the treatment or prevention of a prmt5-mediated disorder
Inventor: MORLEY ANDREW
IPC: A61P35/00
Filed: 2018-03-16
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 20 September 2018 (20.09.2018) WI P0 I PCT omit omioomi om ono i11110 ois (10) International Publication Number WO 2018/167269 Al (51) International Patent Classification: C07D 401/14 (2006.01) C07D 417/12 (2006.01) C07D 405/14 (2006.01) C07D 491/18 (2006.01) C07D 217/04 (2006.01) CO7D 495/04 (2006.01) C07D 217/06 (2006.01) A61P 35/00 (2006.01) CO7D 401/12 (2006.01) A61K 31/4725 (2006.01) CO7D 409/12 (2006.01) A61K 31/4365 (2006.01) CO7D 409/14 (2006.01) (21) International Application Number: PCT/EP2018/056663 (22) International Filing Date: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (25) Filing Language: (26) Publication Language: (30) Priority Data: 1704327.4 16 March 2018 (16.03.2018) English English 17 March 2017 (17.03.2017) GB (71) Applicant: ARGONAUT THERAPEUTICS LIMITED [GB/GB]; The Magdalen Centre, Oxford Science Park, Robert Robinson Avenue, Oxford Oxfordshire OX4 4GA (GB). (72) Inventors: MORLEY, Andrew; c/o 02h Ventures Lim- ited, 23 Science Park, Cambridge Cambridgeshire CB4 OEY (GB). MILLER, Rebecca; c/o Argonaut Therapeu- tics Limited, The Magdalen Centre, Oxford Science Park, Robert Robinson Avenue, Oxford Oxfordshire OX4 4GA (GB). LA THANGUE, Nicholas; c/o Argonaut Therapeu- tics Limited, The Magdalen Centre, Oxford Science Park, Robert Robinson Avenue, Oxford Oxfordshire OX4 4GA (GB). (74) Agent: HGF LIMITED; 1 City Walk, LEEDS Yorkshire LS11 9DX (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, N UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (54) Title: COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER O (57) : The present disclosure relates to compounds suitable for the inhibition of protein arginine methyl-transferase (PRMT), \" in particular PRMT5. These compounds may be for use as therapeutic agents, in particular, agents for use in the treatment and/or 0 prevention of proliferative diseases, such as cancer.